Adoptive transfer of third‐party donor CMV ‐specific T cells for refractory cytomegalovirus infection following umbilical cord blood transplantation

T-cell purity and memory T-cell dominance. Infusions caused mild adverse events, with no severe toxicities. At 6 months post-first infusion, 80% (8/10) achieved durable virological clearance; 60% (6/10) survived at 2 years with sustained CMV control. TPD-derived CMVST infusions are safe and feasible for refractory CMV infection post-UCBT, offering durable virological control while larger studies are needed to confirm efficacy. This trial was registered at www.chictr.org.cn as # ChiCTR2000034951.